Drug Trial News

RSS

Curemark receives FDA clearance for enrollment of children aged 9-12 in CM-AT study for autism

Dr. Joan Fallon, founder and CEO of Curemark, a Rye, New York-based drug research and development company focused on the treatment of Autism and neurological diseases, today announced that the company has received clearance from the Food and Drug Administration (FDA) to commence direct enrollment of children 9-12 years of age into its open-label extension study of CM-AT for children with Autism.

6 Aug 2012

Novel multireceptor-targeted somatostatin analogue found effective against neuroendocrine tumors

A researcher at Moffitt Cancer Center and his international team of colleagues have reported study results on a novel multireceptor-targeted somatostatin analogue called pasireotide (SOM230) manufactured by Novartis Pharma AG.

6 Aug 2012

Rexahn announces completion of RX-3117 exploratory Phase I clinical trial in cancer patients

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed its exploratory Phase I clinical trial of RX-3117 in cancer patients.

6 Aug 2012

Nanobiotix, PharmaEngine partner to commercialize NBTXR3 for soft tissue sarcoma

PharmaEngine, Inc. announced today the execution of an exclusive license and collaboration agreement with France-based Nanobiotix S.A. for the development and commercialization of NBTXR3, currently being investigated in a phase I study with soft tissue sarcoma patients.

6 Aug 2012

TWi Pharmaceuticals completes AC-201 phase II study on type II diabetes

TWi Pharmaceuticals, Inc., a specialty pharmaceutical company based in Taiwan, today announced its fully owned subsidiary, TWi Biotechnology, Inc. has completed a multinational phase II dose-ranging study of AC-201, an orally available IL-1 Beta modulator, in 259 patients with type II diabetes uncontrolled on up to three oral medications.

6 Aug 2012

Caffeine may ease movement symptoms of Parkinson's

While drinking caffeine each day does not appear to help improve sleepiness among people with Parkinson's disease, it may have a benefit in controlling movement, according to new research published in the August 1, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.

3 Aug 2012

Healthpoint Biotherapeutics announces results from HP802-247 Phase 2b trial on venous leg ulcers

Healthpoint Biotherapeutics today announced that the results for its Phase 2b clinical trial investigating the efficacy of HP802-247 in venous leg ulcers is published on The Lancet, beginning August 3, 2012, with Online First access to the article, followed by print publication in the next issue.

3 Aug 2012

Combination of sitagliptin and lansoprazole offers clinical benefits for T1D patients

Sanford Project researchers have reached a critical milestone in a clinical trial testing a combination of two medications to determine if the drugs can help patients with type 1 diabetes (T1D) keep their blood glucose levels under control with less or no insulin. The full number of patients needed to complete this first trial, termed Restore Pancreatic Insulin Response in type 1 diabetes (REPAIR-T1D), has been reached.

2 Aug 2012

Investigational drug shows promise against most severe form of congenital hyperinsulinism

A pilot study in adolescents and adults has found that an investigational drug shows promise as the first potential medical treatment for children with the severest type of congenital hyperinsulinism, a rare but potentially devastating disease in which gene mutations cause insulin levels to become dangerously high.

2 Aug 2012

Combination hormonal therapy improves survival in advanced breast cancer

A study co-authored by a Loyola researcher and published in the New England Journal of Medicine is offering new hope to women with advanced breast cancer.

2 Aug 2012

Combination of anastrozole and fulvestrant extends survival in women with metastatic breast cancer

Results of a SWOG clinical trial published August 2 in the New England Journal of Medicine show the combination of anastrozole and fulvestrant extended the median survival time of women with hormone receptor-positive metastatic breast cancer by more than six months compared to women treated with a standard therapy of anastrozole alone (47.7 months vs 41.3 months).

2 Aug 2012

Caffeine may help control movement in people with Parkinson's

Caffeine, which is widely consumed around the world in coffee, tea and soft drinks, may help control movement in people suffering from Parkinson's. This is the finding of a study conducted at the Research Institute of the McGill University Health Centre (RI MUHC) that was recently published in Neurology, the official journal of the American Academy of Neurology.

2 Aug 2012

Breast cancer drug bevacizumab (Avastin): an interview with Dr Anna Dorothea Wagner

Breast cancer is the most important cancer for women in the developed world. About 20% of all patients diagnosed with breast cancer die of metastatic disease.

1 Aug 2012

Teplizumab type I diabetes prevention study now enrolls younger children

A type I diabetes prevention study that is part of the TrialNet program at Vanderbilt is now enrolling children as young as 8 years old, following an FDA decision allowing the drug Teplizumab (anti-CD3) to be used in younger children.

1 Aug 2012

InSite Vision commences enrollment in BromSite Phase 3 clinical trial

InSite Vision Incorporated today announced that patient enrollment has begun in the first Phase 3 clinical trial of BromSite (ISV-303) for the reduction of pain and inflammation after cataract surgery.

31 Jul 2012

Array BioPharma announces positive results from ARRY-797 Phase 2 trial on osteoarthritis

Array BioPharma today announced that ARRY-797 met its primary endpoint in a randomized, placebo-controlled and active-controlled (oxycodone ER) Phase 2 clinical trial in 157 osteoarthritis patients suffering from moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs (NSAIDs).

31 Jul 2012

GenSpera receives FDA clearance to commence G-202 Phase II trial in prostate cancer

GenSpera, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.

31 Jul 2012

Latrepirdine appears effective in treating Alzheimer's disease in animals

An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain pathology in mouse models of early stage Alzheimer's disease.

31 Jul 2012

Top-line results from Pfizer's tofacitinib Phase 3 study on moderate-to-severe active RA

Pfizer Inc. announced today top-line results from ORAL Start (A3921069), a Phase 3 study of the investigational agent tofacitinib, a novel, oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA).

31 Jul 2012

New drug shows promise for Long QT syndrome

Long QT syndrome, which results from genetic mutation or certain medications, can cause the heart to beat chaotically and the affected person to die suddenly. The chaotic heartbeat is due to abnormal electrical activity in the heart. In an electrocardiogram test, this abnormality appears as a wider-than-normal QT interval, a pattern of "hills" in a map of peaks and valleys corresponding to the heart contracting and relaxing.

30 Jul 2012

Drug Trial News

Curemark receives FDA clearance for enrollment of children aged 9-12 in CM-AT study for autism

Novel multireceptor-targeted somatostatin analogue found effective against neuroendocrine tumors

Rexahn announces completion of RX-3117 exploratory Phase I clinical trial in cancer patients

Nanobiotix, PharmaEngine partner to commercialize NBTXR3 for soft tissue sarcoma

TWi Pharmaceuticals completes AC-201 phase II study on type II diabetes

Caffeine may ease movement symptoms of Parkinson's

Healthpoint Biotherapeutics announces results from HP802-247 Phase 2b trial on venous leg ulcers

Combination of sitagliptin and lansoprazole offers clinical benefits for T1D patients

Investigational drug shows promise against most severe form of congenital hyperinsulinism

Combination hormonal therapy improves survival in advanced breast cancer

Combination of anastrozole and fulvestrant extends survival in women with metastatic breast cancer

Caffeine may help control movement in people with Parkinson's

Breast cancer drug bevacizumab (Avastin): an interview with Dr Anna Dorothea Wagner

Teplizumab type I diabetes prevention study now enrolls younger children

InSite Vision commences enrollment in BromSite Phase 3 clinical trial

Array BioPharma announces positive results from ARRY-797 Phase 2 trial on osteoarthritis

GenSpera receives FDA clearance to commence G-202 Phase II trial in prostate cancer

Latrepirdine appears effective in treating Alzheimer's disease in animals

Top-line results from Pfizer's tofacitinib Phase 3 study on moderate-to-severe active RA

New drug shows promise for Long QT syndrome

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

Latest News